Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Preliminary Pharmacodynamics of Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy in Patients With Relapsed/Refractory Autoimmune Diseases
NCT07490275Phase 1Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jul 2026
- Primary completion
- Dec 2028
- Modality
- CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of Allogeneic CD19/BCMA-targeted CAR-gamma-delta T cells in systemic lupus erythematosus (SLE), systemic sclerosis (SSc), inflammatory myopathy (IIM) and 2 more, sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Adverse Events at 6 months and Incidence of Dose-Limiting Toxicities at 28 days. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
Allogeneic CD19/BCMA-targeted CAR-gamma-delta T cells
03
Conditions
systemic lupus erythematosus (SLE)systemic sclerosis (SSc)inflammatory myopathy (IIM)Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)Thrombocytopenia
Beyond the preview
Go deeper on NCT07490275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07490275.